Reference is to Printer's Date 3/20/14-H.
Amend the bill, as and if amended, by deleting SECTION 1 in its entirety and inserting:
/ SECTION 1. Paragraph 27 of Section 44-53-110 of the 1976 Code is amended to read:
"'Marijuana' means:
(1) all species or
variety of the marijuana plant and all parts thereof whether
growing or not;
(2) the seeds of the
marijuana plant;
(3) the resin extracted
from any part of the marijuana plant;
(4) every compound,
manufacture, salt, derivative, mixture, or preparation of the
marijuana plant, marijuana seeds, or marijuana resin.
'Marijuana' does not mean:
(1) the mature stalks
of the marijuana plant or fibers produced from these stalks;
(2) oil or cake made
from the seeds of the marijuana plant, including cannabidiol
derived from the seeds of the marijuana plant;
(3) any other compound,
manufacture, salt, derivatives, mixture, or preparation of the
mature stalks (except the resin extracted therefrom),
including cannabidiol derived from mature stalks ;
(4) the sterilized seed
of the marijuana plant which is incapable of
germination;
(5) for
persons participating in a clinical trial or in an expanded
access program related to administering cannabidiol for the
treatment of severe forms of epilepsy pursuant to Article 18,
Chapter 53, Title 44, a drug or substance approved for the use
of those participants by the federal Food and Drug
Administration;
(6) for
persons, or the persons' parents, legal guardians, or other
caretakers, who have received a written certification from a
physician licensed in this State that the person has been
diagnosed by a physician as having Lennox Gastaut Syndrome,
Dravet Syndrome, also known as 'severe myoclonic epilepsy of
infancy', or any other severe form of epilepsy that is not
adequately treated by traditional medical therapies, the
substance cannabidiol, a nonpsychoactive cannabinoid, or any
compound, manufacture, salt, derivative, mixture, or preparation
of any plant of the genus cannabis that contains three-tenths of
one percent or less of tetrahydrocannabinol and more than
fifteen percent of cannabidiol.
(a)
For purposes of this item, written certification
means a document dated and signed by a physician stating that
the patient has been diagnosed with Lennox Gastaut Syndrome,
Dravet Syndrome, also known as 'severe myoclonic epilepsy of
infancy', or any other severe form of epilepsy that is not
adequately treated by traditional medical therapies and the
physician's conclusion that the patient might benefit from the
medical use of cannabidiol.
(b)
A physician is not subject to detrimental
action, including arrest, prosecution, penalty, denial of a
right or privilege, civil penalty, or disciplinary action by a
professional licensing board for providing written certification
for the medical use of cannabidiol to a patient in accordance
with this section." /
Renumber sections to conform.
Amend title to conform.